Latest News

I am pleased to share to with you my letter-to-the-editor from the Feb 20th, issue of NEJM (p 781). I responded to a Nov 14th, National Heart, Lung, and Blood Institute...

Read More

Challenges of Rare Diseases

Management of chronic, lifelong rare diseases is often fragmented, expensive, and stressful.  Patients and caregivers find themselves with a host of unmet medical needs.  To address those needs, new therapies for rare diseases must continually evolve:

  • Often misdiagnosed
  • High rates of comorbidities
  • Complex pathology and costly treatments
  • Underpowered clinical trials requiring long-term surveillance
  • Passionate, highly specialized, and team-oriented providers
  • Diverse stakeholders with very specific information needs
  • Influential advocacy groups

From Bench to Bedside to Better Outcomes

As patients with rare diseases face a lifetime of adapting to challenges, new therapeutic interventions should be appropriately attuned to patient needs.  Churchill's lifecycle approach - from bench to bedside to better outcomes - includes comprehensive, multidisciplinary programs designed to translate bench science into bedside clinical practice, while aligning therapeutic advances with patient needs to improve long-term outcomes.

Churchill and Rare Diseases

Churchill was founded in 1989 by practicing clinicians needing information about the impact of new therapies on patients oftenexcluded from randomized controlled trials.  Churchill designs comprehensive communications, education, advocacy, and outcomes programs incorporating the perspectives of providers, patients, and caregivers.  Our multidisciplinary account teams apply a clinical practice model that includes physicians, pharmacists, PAs, nurses, and other healthcare professionals with experience managing patients with rare diseases.